Treatment of Patients With Gastric Cancer by Surgery, Radiotherapy, and Chemotherapy: Preliminary Results of an EORTC Randomized Study

  • J. C. Goffin
  • D. Machin
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 68)

Abstract

The 5-year survival rate of gastric cancer is between 8% and 9% and has not improved over the past 3 decades. In the American literature [1–3, 5, 6, 8, 9, 11], it is reported that the application of adjuvant chemotherapy after gastric resection has led to an improvement in the survival rate. Some studies in locally unresectable gastric cancer record an improved survival when 5-fluorouracil (5-FU) is combined with local radiotherapy [1, 10]. Reitemeier et al. [10] and Heidelberger et al. [4] pointed out that certain transplanted tumors showed a regression as well as prolonged survival when treated by irradiation therapy in addition to 5-FU. Working on this basis, Moertel et al. studied the effect of combined 5-FU and supervoltage radiotherapy and found that they gave significant objective asymptomatic palliation in some patients having gastrointestinal cancer [7]. It is thought that 5-FU acts as a radiosensitizor or at least as a synergistic adjuvant when given simultaneously with radiotherapy to the primary tumor. Moreover, 5-FU is given systematically and thus exerts its desirable effects on the floating cells in the circulation as well as on metastatic foci in distant organs.

Keywords

Toxicity Adenocarcinoma Diarrhea Pyrimidine Leukopenia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. 1.
    Childs, D. S., Moertel, C. G., Holbrook, M. A., Reitemeier, R. J., Colby, M.: Treatment of unresectable adenocarcinomas of the stomach with a combination of 5-fluorouracil and radiation. Am. J. Roentgenol. 102, 541–544 (1968).Google Scholar
  2. 2.
    Comis, R. L., Carter, S. K.: A review of chemotherapy in gastric cancer. Cancer 74, 1576–1586 (1974).CrossRefGoogle Scholar
  3. 3.
    Comis, R. L., Carter, S. K.: Integration of chemotherapy into combined modality treatment of solid tumors. III. Gastric cancer. Cancer Treat. Rev. 1, 221–238 (1974).CrossRefGoogle Scholar
  4. 4.
    Heidelberger, C., Griesbach, L., Montag, B. J., Mooren, D., Cruz, O., Schnitzerr, J., Grunberg, E.: Studies on fluorinated pyrimidines. II. Effect on transplanted tumors. Cancer Res. 18, 305–317 (1958).PubMedGoogle Scholar
  5. 5.
    Hurley, J. D., Ellison, E. H., Carey, L. L.: Treatment of advanced cancer of the gastrointestinal tract with antitumor agents. Gastroenterology 41, 557–562 (1961).PubMedGoogle Scholar
  6. 6.
    Jacobs, E. M., Reeves, W. J., Wood, D. A., Pugh, R., Braumwald, J., Bateman, J. R.: Treatment of cancer with weekly intravenous 5-fluorouracil. Cancer 27, 1302–1305 (1971).PubMedCrossRefGoogle Scholar
  7. 7.
    Moertel, C. G., Reitemeier, R. J.: Advanced gastrointestinal cancer. In: Clinical management and chemotherapy, p. 164. New York: Harper & Row 1969.Google Scholar
  8. 8.
    Moore, G. E., Bross, I. D. J., Ausman, R., Nadler, S., Jones, R., Slack, N., Rimm, A. A.: Effects of 5-fluorouracil in 389 patients with cancer. Cancer Chemother. Rep. 52, 641–653 (1968).PubMedGoogle Scholar
  9. 9.
    Nadler, S. H., Moore, G. E.: A clinical study of 5-fluorouracil. Surg. Gynecol. Obstet. 127, 1210–1214 (1968).PubMedGoogle Scholar
  10. 10.
    Reitemeier, R. J., Moertel, C. G., Hahn, R. G.: Combination chemotherapy in gastrointestinal cancer. Cancer Res. 30, 1425–1428 (1970).PubMedGoogle Scholar
  11. 11.
    Rochlin, D. B., Smart, C. R., Silva, A.: Chemotherapy of malignancies of the gastrointestinal tract. Am. J. Surg. 109, 43–46 (1965).PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1979

Authors and Affiliations

  • J. C. Goffin
  • D. Machin

There are no affiliations available

Personalised recommendations